FANCL Antikörper (C-Term)

Produktnummer ABIN1881336

Dieses Anti-FANCL-Antikörper ist ein Kaninchen Polyklonal-Antikörper zur Detektion von FANCL in WB. Geeignet für Human. Dieses Primary Antibody wurde in 5+ Publikationen zitiert.

Kurzübersicht für FANCL Antikörper (C-Term) (ABIN1881336)

Target: FANCL (Fanconi Anemia, Complementation Group L (FANCL))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser FANCL Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Klon: RB23901

Produktdetails anti-FANCL Antikörper

Bindungsspezifität: AA 274-302, C-Term

Aufreinigung: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This FANCL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 274-302 amino acids from the C-terminal region of human FANCL.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: WB: 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Haltbarkeit: 6 months

Referenzen für anti-FANCL Antikörper (ABIN1881336)

Zhang, Zhao, Park, Wang, Dyer, Liu, Klee, McNiven, Tindall, Molina, Fei: "FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth." in: The Journal of clinical investigation, Vol. 120, Issue 5, pp. 1524-34, (2010) (PubMed).

García, Fernández, Osorio, Barroso, Fernández, Urioste, Benítez et al.: "Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer ..." in: Carcinogenesis, Vol. 30, Issue 11, pp. 1898-902, (2009) (PubMed).

Longerich, San Filippo, Liu, Sung: "FANCI binds branched DNA and is monoubiquitinated by UBE2T-FANCL." in: The Journal of biological chemistry, Vol. 284, Issue 35, pp. 23182-6, (2009) (PubMed).

McWilliams, Bamlet, de Andrade, Rider, Couch, Cunningham, Matsumoto, Rabe, Hammer, Petersen: "Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk." in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, Vol. 18, Issue 9, pp. 2549-52, (2009) (PubMed).

Hess, Ameziane, Schuurhuis, Errami, Denkers, Kaspers, Cloos, Joenje, Reinhardt, Ossenkoppele, Zwaan, Waisfisz: "Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia." in: Cellular oncology : the official journal of the International Society for Cellular Oncology, Vol. 30, Issue 4, pp. 299-306, (2008) (PubMed).

Details zu FANCL

Target: FANCL (Fanconi Anemia, Complementation Group L (FANCL))

Andere Bezeichnung: FANCL

Hintergrund: The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity, they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group L. Alternative splicing results in two transcript variants encoding different isoforms.

Molekulargewicht: 42905

NCBI Accession: NP_001108108, NP_060532

UniProt: Q9NW38

Pathways: DNA Reparatur